IXI.L

IXICO plc [IXI.L] Stock Forecast

Buy or Sell ? Support and Resistance

What is MACD and how to read it?

How RSI can help?

Stock Summary

EPS has been increasing for the past 3 years (Yearly statements)

EPS has been increasing for the past 3 quarters (Quarter statements)

EPS has increased from the previous quarter and is now positive. (Quarter statements)

Does not have any significance market cap ($18.06M)

Profit margins (0.02%) are lower than the previous year (0.17%)

IXI.L has less than 1 year of cash runway

Top 10 Correlated Stocks

IXI.L

Financial details

Company Rating

Buy

Market Cap

18.06M

Income

157K

Revenue

7.02M

Book val./share

0.16

Cash/share

0.16

Dividend

Dividend %

Employees

Optionable

Shortable

Yes

Earnings

05 Dec 2022

P/E

Forward P/E

PEG

-2.1

P/S

2.53

P/B

1.54

P/C

237.5

P/FCF

-43.02

Quick Ratio

3.82

Current Ratio

5.96

Debt / Equity

LT Debt / Equity

0.04

EPS (TTM)

EPS next Y

EPS next Q

EPS this Y

65.77%

EPS next Y

EPS next 5Y

EPS last 5Y

NAN%

Revenue last 5Y

17.46%

Revenue Q/Q

EPS Q/Q

SMA20

4.38%

SMA50

14.62%

SMA100

0.13%

Inst Own

Inst Trans

ROA

ROE

ROC

0.01%

Gross Margin

64%

Oper. Margin

Profit Margin

Payout

Shs Outstand

48.15M

Shs Float

16.97M

Target Price

52W Range

30.0-91.0

52W High

-58.24%

52W Low

+26.67%

RSI

53.07

Rel Volume

0.02

Avg Volume

17.82K

Volume

330

Perf Week

-2.56%

Perf Month

16.92%

Perf Quarter

-2.56%

Perf Half Y

-8.43%

Beta

1.0175

Volatility

0.58%, 1.84%

Prev Close

Price

Change

Financial Performance

Yearly Fundamentals Overview

Last date of statement is 2021-09-30

Metric	2017-09-30	2018-09-30	2019-09-30	2020-09-30	2021-09-30
Revenue per share	0.15	0.16	0.16	0.2	0.2
Net income per share	-0.06	-0.02	0.01	0.02	0.03
Operating cash flow per share	-0.02	0.01	0	0.04	0.01
Free cash flow per share	-0.03	0.01	-0.01	0.02	-0.03
Cash per share	0.09	0.23	0.16	0.17	0.14
Book value per share	0.11	0.22	0.17	0.19	0.24
Tangible book value per share	0.1	0.22	0.16	0.18	0.18
Share holders equity per share	0.11	0.22	0.17	0.19	0.24
Interest debt per share	0	0	0	0	0.01
Market cap	9.16M	9.79M	33.92M	47.04M	33.4M
Enterprise value	6.74M	1.93M	26.66M	39.3M	27.31M
P/E ratio	-6	-14.66	78.52	49.41	21.2
Price to sales ratio	2.23	1.82	4.49	4.93	3.63
POCF ratio	-14.22	26.97	-260.92	24.31	54.48
PFCF ratio	-13.21	34	-52.43	59.31	-21.67
P/B Ratio	3.14	1.34	4.28	5.16	2.98
PTB ratio	3.14	1.34	4.28	5.16	2.98
EV to sales	1.64	0.36	3.53	4.12	2.97
Enterprise value over EBITDA	-3.94	-3.01	55.77	29.91	15.25
EV to operating cash flow	-10.47	5.32	-205.05	20.31	44.55
EV to free cash flow	-9.73	6.7	-41.2	49.56	-17.72
Earnings yield	-0.17	-0.07	0.01	0.02	0.05
Free cash flow yield	-0.08	0.03	-0.02	0.02	-0.05
Debt to equity	0	0	0	0	0.05
Debt to assets	0.35	0.29	0.26	0.25	0.21
Net debt to EBITDA	1.41	12.26	-15.2	-5.88	-3.4
Current ratio	2.74	3.4	3.63	3.85	4.51
Interest coverage	0	0	0	46.78	52.55
Income quality	0.42	-0.54	-0.3	2.03	0.39
Dividend Yield	0	0	0	0	0
Payout ratio	0	0	0	0	0
Sales general and administrative to revenue	0.47	0.45	0.36	0.3	0.27
Research and developement to revenue	0.27	0.17	0.11	0.12	0.12
Intangibles to total assets	0.03	0	0.03	0.07	0.19
Capex to operating cash flow	0.08	-0.21	3.98	-0.59	-3.51
Capex to revenue	-0.01	-0.01	-0.07	-0.12	-0.23
Capex to depreciation	-0.26	-0.49	-4.62	-2.61	-3.54
Stock based compensation to revenue	0.05	0.03	0.01	0.02	0.02
Graham number	0.37	0.31	0.19	0.3	0.42
ROIC	-0.46	-0.11	0.05	0.09	0.1
Return on tangible assets	-0.35	-0.06	0.04	0.08	0.14
Graham Net	0.03	0.14	0.1	0.11	0.08
Working capital	2.75M	7.22M	7.31M	7.61M	8.06M
Tangible asset value	2.79M	7.29M	7.63M	8.32M	8.51M
Net current asset value	2.73M	7.22M	7.31M	7.31M	7.43M
Invested capital	0	0	0	0.02	0.05
Average receivables	0	0	0	0	0
Average payables	223K	257.5K	386.5K	176K	455K
Average inventory	0	0	0	0	0
Days sales outstanding	0	0	0	0	0
Days payables outstanding	55.18	55.71	83.2	20.16	84.62
Days of inventory on hand	0	0	0	0	0
Receivables turnover	0	0	0	0	0
Payables turnover	6.61	6.55	4.39	18.1	4.31
Inventory turnover	0	0	0	0	0
ROE	-0.52	-0.09	0.05	0.1	0.14
Capex per share	0	0	-0.01	-0.02	-0.05

Quarterly Fundamentals Overview

Last date of statement is 2019-03-31 for Q2

Metric	2015-09-30	2016-03-31	2017-03-31	2018-03-31	2019-03-31
Revenue per share	0.05	0.03	0.04	0.04	0.04
Net income per share	-0.02	-0.02	-0.01	0	0
Operating cash flow per share	-0.02	-0.02	-0.01	0	0
Free cash flow per share	-0.02	-0.02	-0.01	0	0
Cash per share	0.13	0.13	0.1	0.08	0.16
Book value per share	0.18	0.21	0.14	0.08	0.16
Tangible book value per share	0.16	0.21	0.14	0.08	0.16
Share holders equity per share	0.18	0.21	0.14	0.08	0.16
Interest debt per share	0	0	0	0	0
Market cap	4.74M	9.62M	6.87M	11.99M	12.87M
Enterprise value	2.81M	6.44M	4.07M	9.29M	5.41M
P/E ratio	-3.97	-4.54	-4.5	-17.94	29.78
Price to sales ratio	6.09	12.37	6.68	8.89	6.81
POCF ratio	-14.42	-25.06	-42.65	132.07	-395.88
PFCF ratio	-13.94	-24.68	-39.64	166.46	-79.54
P/B Ratio	1.75	1.88	1.88	4.46	1.7
PTB ratio	1.75	1.88	1.88	4.46	1.7
EV to sales	3.61	8.28	3.96	6.89	2.86
Enterprise value over EBITDA	-9.03	-10.21	-9.51	-57.95	45.3
EV to operating cash flow	-8.54	-16.77	-25.26	102.33	-166.56
EV to free cash flow	-8.26	-16.52	-23.47	128.98	-33.47
Earnings yield	-0.06	-0.06	-0.06	-0.01	0.01
Free cash flow yield	-0.07	-0.04	-0.03	0.01	-0.01
Debt to equity	0	0	0	0	0
Debt to assets	0.36	0.25	0.31	0.45	0.25
Net debt to EBITDA	6.22	5.05	6.55	16.84	-62.37
Current ratio	2.6	3.7	3.14	2.15	3.9
Interest coverage	0	0	0	0	0
Income quality	1.1	0.72	0.42	-0.54	-0.3
Dividend Yield	0	0	0	0	0
Payout ratio	0	0	0	0	0
Sales general and administrative to revenue	0.67	0.61	0.47	0.45	0.36
Research and developement to revenue	0.4	0.51	0.31	0.19	0.13
Intangibles to total assets	0.07	0	0	0	0
Capex to operating cash flow	0.03	0.02	0.08	-0.21	3.98
Capex to revenue	-0.01	-0.01	-0.01	-0.01	-0.07
Capex to depreciation	-0.3	-0.07	-0.26	-0.49	-4.62
Stock based compensation to revenue	0.03	0.04	0.05	0.03	0.01
Graham number	0.28	0.32	0.21	0.09	0.09
ROIC	-0.12	-0.12	-0.09	-0.07	0.01
Return on tangible assets	-0.08	-0.08	-0.07	-0.03	0.01
Graham Net	0.03	0.06	0.04	0.01	0.1
Working capital	2.35M	3.94M	3.46M	2.54M	7.4M
Tangible asset value	2.41M	0	0	0	0
Net current asset value	2.29M	3.67M	3.43M	2.53M	7.4M
Invested capital	0	0	0	0	0
Average receivables	0	0	0	0	0
Average payables	552K	1.01M	1.17M	1.47M	1.64M
Average inventory	0	0	0	0	0
Days sales outstanding	0	0	0	0	0
Days payables outstanding	100.68	275.36	325.53	357.89	350.52
Days of inventory on hand	0	0	0	0	0
Receivables turnover	0	0	0	0	0
Payables turnover	0.89	0.33	0.28	0.25	0.26
Inventory turnover	0	0	0	0	0
ROE	-0.11	-0.1	-0.1	-0.06	0.01
Capex per share	0	0	0	0	0

Frequently Asked Questions

What is IXICO plc stock symbol ?

IXICO plc is a GB stock and trading under the symbol IXI.L

What is IXICO plc stock quote today ?

IXICO plc stock price is $38 today.

Is IXICO plc stock public?

Yes, IXICO plc is a publicly traded company.

Something similar

Top by Market Cap

Same Sector

Top Correlated Stocks

Similar Market Cap

Company Profile

Volume Average 17.82K
Market Capitalization 18.06M
Employee 93
CEO Giulio Cerroni
Headquarters LONDON,GB
IPO Date 2013-09-04
Website https://ixico.com

IXICO plc provides data analytics services to the biopharmaceutical industry in the United Kingdom, Switzerland, Netherlands, Ireland, rest of Europe, the United States, and internationally. Its services include collection, analysis, management, and reporting on data generated in the course of a clinical study. The company's technologies comprise Assessa, a secure online digital platform that provides clinical decision support for patient selection and post-marketing surveillance; and TrialTracker, a platform that delivers imaging services designed to manage the complex imaging workflow from image upload, quality control, and reading/analysis to reporting and data transfer. Its focused therapeutic areas include Alzheimer's, Parkinson's, Huntington's, Multiple Sclerosis and other demyelinating diseases, Progressive Supranuclear Palsy, and other rare neurological diseases. The company also engages in the data collection, optimization, and analytics of rare neurological disorders; offers drug development analytics, imaging operation services, and post marketing surveillance services, as well as consultancy services; and provides end-to-end services, such as trail design and consultation, project management, imaging site set-up and management, data management, reading and analysis, and regulatory pathway. IXICO plc was incorporated in 1995 and is based in London, the United Kingdom.